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Background: Breast conservation therapy (BCS) after neoadjuvant chemotherapy (NCT) can improve patients’
quality of life. Currently used intraoperative examination for negative margins may not be sufficient to detect
microresidual foci, which are a risk factor for local recurrence. This study was conducted to investigate the shrinking
pattern of breast cancer and residual tumors as a risk factor for BCS after NCT.
Methods: Ninety women with stage II or III invasive ductal carcinoma who achieved partial response after NCT
with paclitaxel and epirubicin were enrolled. All patients had undergone modified radical mastectomy. One-half of
the surgical specimens were subjected to subserial sectioning. Pathological changes of tumor bed and
pericancerous tissues were examined with an optical microscope. The levels of estrogen receptors, progesterone
receptors and HER2 were analyzed by immnohistochemical staining.
Results: The residual tumors were classified into three types according to their microscopic morphology: solitary
lesion, multifocal and patchlike lesions, and main residual tumor with satellite lesions. Type I residual tumors were
found in 55 patients (61%), type II in 30 patients (33%) and type III in 5 patients (6%). Types II and III were often
associated with larger primary tumors. The types of residual tumors were not correlated with the status of hormone
receptors or HER2.
Conclusion: Three types of residual tumors were observed after NCT. The solitary residual tumor is most common,
but main residual tumors with satellite lesions are most likely to cause local recurrence after BCS. Subserial
sectioning would improve the identification of microfoci and patient survival after BCS.
Keywords: Breast cancer, Breast conservation surgery, Neoadjuvant chemotherapy, Residual tumor,
Subserial sectionBackground
Breast conservation therapy (BCS) can improve patients’
quality of life. Large-scale, multicenter, randomized con-
trolled trials have shown no significant difference in
recurrence-free survival and overall survival (OS) be-
tween patients who have undergone BCS and those who
have had radical mastectomy [1] in early breast cancer.
BCS entails a local recurrence rate of 10% in early breast
cancer, so there is an emphasis on ways of decreasing
local recurrence rate after BCS.* Correspondence: jcbd@medmail.com.cn
Breast Disease Center, Southwest Hospital, Third Military Medical University,
29 Gaotanyan Street, Chongqing 400038, China
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reproduction in any medium, provided the orNeoadjuvant chemotherapy (NCT) can make more pa-
tients suitable for BCS by downstaging primary tumors
[2,3]. However, NCT-downstaged tumors have a higher
local recurrence rate than the primary tumors suitable
for BCS, which may be a result of incomplete removal of
cancer tissues [4].
Intraoperative frozen section examination is used to
ensure negative margins. Some patients still develop
local recurrence after BCS, however, despite negative
margins reached. Recurrence is often near the site of the
original tumor. Concentric or patchlike residual tumors
remain at cancer sites after NCT. The patchlike residual
cancer is one of the major factors underlying local recur-
rence after BCS [5]. Conventional pathological methodstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tern and may miss microfoci, owing to specimen limita-
tion. In this study, subserial sectioning was used to
check the shrinking pattern and identify residual tumors
after NCT. Our study should provide information that
will help reduce local recurrence and enhance the sur-
vival of patients who have undergone BCS.
Methods
Patients and general protocols
All patients were enrolled and treated at the Breast
Disease Center of the Southwest Hospital between 1
September 2007 and 1 October 2009. We enrolled 90
patients with stage II or III breast cancer. All patients
were females from age 28 to about 70 yr (mean:
48.99 yr) (Table 1). Cancers were confirmed by core nee-
dle biopsy before NCT. Before chemotherapy or surgery,
color Doppler ultrasound and X-ray examinations were
performed to evaluate tumor size. Patients were given a
paclitaxel and epirubicin (TE) regimen (paclitaxel
175 mg/m2, epirubicin HCl 80 mg/m2 iv, 21 d per
round) for three to eight rounds. Routine blood, liver,
kidney and heart function was examined before each
round of treatment. Prior to surgery, ultrasound and X-
ray examinations were performed again, the largest
tumor diameter after chemotherapy was measured and
lesion calcification and type or any small satellite lesions
near the main mass were observed. All protocols were
approved by the Ethics Committee of Third Military
Medical University, and every patient signed the in-
formed consent form.
Inclusion criteria
1. Stage II (diameter of 2 to 5 cm) or stage III (>5 cm
without involvement of skin or chest wall) invasive
ductal carcinoma confirmed by core needle biopsy.Table 1 Patients’ clinical characteristics
Characteristics No. of patients %
Age (yr)
≤ 40 18 20.0
41 to 60 65 72.2
>60 7 7.8
Chemotherapy (cycle)





T3 13 14.42. No involvement of lymph node determined by
axillary dissection.
3. Color ultrasound and X-ray examinations showing
that the primary tumor was a solitary lesion.
4. Response Evaluation Criteria in Solid Tumors
(RECIST) [6] was used and partial response reached.
5. No chemotherapy, radiotherapy, hormonal therapy
or any resection biopsy before surgery.
6. Not fit for BCS or patient had personally asked for
modified radical mastectomy.
Exclusion criteria
1. Patients diagnosed with primary cancer with
multiple lesions.
2. Partial response not achieved after chemotherapy.
3. Clinically complete relief obtained after
chemotherapy.
4. Patients undergoing BCS.
5. Tumor invasion of chest and skin.
6. Patients with stage I or IV breast cancer.
7. Patients who had undergone chemotherapy,
radiotherapy, endocrine therapy and resection
biopsy previously.
Subserial section of whole breast
Subserial sections of the whole breast were prepared from
the specimens. The sample was put on a board with the
cutting surface facing downward, surrounding fat tissue
and aponeurosis were cut off and the spindle-shaped skin
border was sutured with silk and fixed to the board to pre-
vent skin retraction. The specimen was stored in a −20°C
ice box for 24 h, then parallel lines were drawn every
5 mm from the cutting edge to the margin of the half
breast sample. Using these lines, 5-mm tissue pieces were
cut, retrimmed to remove surrounding fat tissue and num-
bered sequentially. The tissue pieces were fixed in 10% for-
malin for 48 h, dehydrated with acetone and anhydrous
alcohol for 12 and 24 h separately, soaked in chloroform
and xylene separately for 24 h each, wax-dipped for
24 hours (melting point, 56°C to 58°C) and embedded in
paraffin. Eight- to twelve-micrometer sections were cut
using a Leica RM2016 slicer (Leica Biosystems, Nussloch,
Germany) and stained with hematoxylin and eosin.
Histological evaluation was done according to the
method of Miller and Payne [7]. The shape, distribution
and size of the residual lesion, as well as hyperplasia of
fibrous tissue, lymphocyte infiltration and change of
pericancerous tissue, were recorded.
Detection of estrogen receptors, progesterone receptors
and HER2
The levels of estrogen receptors (ERs), progesterone re-
ceptors (PRs) and HER2 in preoperative core needle
Wang et al. World Journal of Surgical Oncology 2013, 11:166 Page 3 of 6
http://www.wjso.com/content/11/1/166biopsy tissues and final surgical specimens were exa-
mined by immunohistochemical staining. ER and PR
levels were determined by Allred score [8], which is
based on the percentage of tumor cells (PS), intensity of
the staining (IS) and total score (TS = PS + IS). PS repre-
sented the estimated proportion of tumor cells staining
positive as follows: 0 (none), 1 (tumor cells staining posi-
tive < 1%), 2 (tumor cells staining positive between 1%
and 10%), 3 (tumor cells staining positive between 10%
and 33%), 4 (proportion of tumor cells staining positive
between 33% and 67%) and 5 (proportion of tumor cells
staining positive >67%). IS represented the average inten-
sity of the positive cells as follows: 0 (none), 1 (weak),
2 (intermediate) and 3 (strong). PS and IS were then added
to obtain TS as follows: negative (0 to about 2), 1+ (3 to
about 4), 2+ (5 to about 6), and 3+ (7 to about 8).
A herceptin test [9] was used to detect HER2 levels. It
was scored according to cell membrane staining, indi-
cated as 3+ (strong, complete membrane staining in
>10% of tumor cells), 2+ (weak to moderate, complete
membrane staining in >10% of the tumor cells), 1+ (faint
membrane staining involving only a portion of the mem-
brane in >10% of tumor cells) or 0 (no staining or faint
staining in < 10% of the tumor cells).
Statistical analysis
SPSS version 13.0 software (SPSS, Inc, Chicago, IL,
USA) was used for data analysis. A paired test was ap-
plied for matched data and χ2 and nonparametric tests
were done for other data, with P < 0.05 regarded as
significant.
Results
Light microscopic observation of pathological changes in
tumor bed and pericancerous tissues after NCT
There were fibroplasias and lymphocyte infiltration to
different degrees near the degenerated cancer site and
small blood vessels (Figure 1). Histological classifica-
tion after chemotherapy showed grade I in 4 cases,
grade II in 26, grade III in 51 and grade IV in 10.
Twenty-four cases with severe lymphocyte infiltration
and sixty-six with light to moderate lymphocyte infil-
tration were found. Five cases had an intraductal car-
cinoma component.
Morphological typing of residual breast cancer after NCT
There were three microscopic morphological types of
residual breast cancer after NCT. Type I comprised
solitary lesions in the fibrotic tumor bed with exten-
sive lymphocyte infiltration near the cancer lesion
(Figure 1A). Type II involved fibrotic changes in the
tumor bed, which divided the residual cancer structure
into several lesions with irregular shapes and patchlike
shapes of different sizes (Figure 1B). Type III had amain cancer lesion and one or two small satellite le-
sions at least 1.0 cm away from it (10 mm to about
25 mm) visible in the fibrotic cancer bed with or with-
out scattered cancer cell structures around the cancer
lesion (Figures 1C1 and 1C2). Among the 90 patients,
type I residual cancer was found in 55 (61%), type II
in 30 (33%) and type III in 5 (6%). Among the patients
with type III residual cancer, four had one satellite le-
sion and one had two satellite lesions.
Mammary X-ray features of calcification and satellite
lesions of breast cancer after chemotherapy
Mammary X-ray examination after NCT showed calcifi-
cation in nine cases. Three had clusterlike granules
around the tumor, one had linelike calcification distrib-
uted along the breast ducts and five showed large calcifi-
cation particles located within the tumor. No satellite
lesions were found by X-ray examination.
Maximum tumor diameters measured by ultrasonography
and pathological examination
Tumor size was measured after NCT using color Dop-
pler ultrasound. The maximum diameter was 8 to
49 mm (mean, 19.2 mm). Pathological observation of
postoperative subserial sections of whole breasts showed
that the maximum tumor diameter was 5 to 51 mm
(mean, 21.7 mm). The paired t-test showed no statistical
difference in stage I breast cancer (P > 0.05), but signifi-
cant differences in stages II and III breast cancer (P <
0.05) between the two examination methods were found.
Relationship between types of residual tumor, age and
menstrual status
The proportions of three age groups (≤ 40, 41 to 60 and
>60 years of age) were 21.8%, 70.9% and 7.3%, respect-
ively, for type I residual tumors; 13.3%, 80.0% and 6.7%,
respectively, for type II residual tumors; and 20.0%,
60.0% and 20.0%, respectively, for type III residual tu-
mors. There was no statistically significant difference
among the three types (P > 0.05). The proportions of
postmenopausal patients in the three types were 20.0%,
56.7% and 20.0%, respectively, which had no statistical
significance (Table 2).
Relationship between types of residual tumor and
primary tumor T stage
For type I residual tumors, the proportions of T1, T2
and T3 primary tumors were 20.0%, 76.4% and 3.6%, re-
spectively. There were 10.0%, 56.7% and 33.3% of type II
residual tumors resulting from T1, T2, and T3 primary
tumors, respectively, whereas 20.0%, 60.0% and 20.0% of
type III residual tumors came from T1, T2, and T3 pri-
mary tumors after NCT. The primary tumor stage distri-
bution among the three types of residual cancer was
Figure 1 Three types of residual cancers. (A) Type I residual cancer. Solitary residual breast cancer can be seen (arrow). There is a large
quantity of lymphocyte infiltration in the margin of the cancer lesion. There are no residual cancer cells, cancer cell clumps or satellite lesions
near the cancer lesion. (B) Type II residual cancer. Two residual cancer lesions can be seen (arrows), and there is fibrotic change between the
lesions. (C) Type III residual tumor. Solitary residual lesion (C1, arrow) and satellite lesion 1.5 cm away from the main lesion (C2, arrow) can be
seen (hematoxylin and eosin stain; original magnification, ×40).
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sidual tumors had higher occurrences in patients with
larger primary tumors.
Relationship between types of residual tumor and levels
of ER, PR and HER2
The positive rates of ER, PR and HER2 before and after
NCT were not statistically different among patients with
three types of residual tumors (P > 0.05) (Table 3). The
changes in expression levels of ER, PR and HER2 among
three types of residual cancers also were not statistically
different (P > 0.05) (Table 4).
Discussion
It has been shown that patients who have undergone
modified radical mastectomy have a long-term survival
rate similar to that of those who have undergone radical
mastectomy [10-13]. NCT can make 23% of primary
breast cancers that are otherwise unfit for BCS manage-
able with BCS through downstaging [4]. Wolmark et al.Table 2 Relationship between types of residual tumor with ag
Types n Age (yr) (%)
≤ 40 41 to 60
Type I 55 12 (21.8) 39 (70.9)
Type II 30 4 (13.3) 24 (80.0)
Type III 5 1 (20.0) 3 (60.0)
χ2
P valuea 0.393
aKruskal-Wallis test and χ2 test.[3] reported a local recurrence rate of 10.7% in
postchemotherapy patients treated with BCS, 7.6% in pa-
tients with primary tumors fit for BCS and 15.9% in pa-
tients with primary breast cancer unfit for BCS through
downstaging by chemotherapy. The local recurrences
were found mostly around the site of operation.
MRI observations of tumor morphological changes
after NCT have been classified by contraction patterns
into concentric contraction and patchlike contraction
[2]. About 70% of residual tumors were previously found
to be solitary and 30% were patchlike [5]. A negative
surgical margin of BCS is closely associated with local
recurrence-free and metastasis-free survival [3,4]. It was
difficult to ensure negative surgical margins in BCS pa-
tients who had multifocal residual tumors, which was
one of the factors that caused local recurrence [14,15].
However, some patients with solitary residual tumors
that had negative surgical margins still developed local
recurrence. There might be microfoci that are missed
by conventional histological sections due to samplee and menstrual status
Menstrual status (%)
>60 Postmenopausal Premenopausal
4 (7.3) 22 (20.0) 33 (80.0)
2 (6.7) 17 (56.7) 13 (43.3)
1 (20.0) 1 (20.0) 4 (80.0)
3.465
0.177
Table 3 Relationship between types of residual tumor and expression of ERa, PRa and HER2b
Types No. of ER (%) prior to NCT No. of ER (%) after NCT
- + to about +++ χ2 P value - + to about +++ χ2 P value
Type I 21 (38.2) 34 (61.8) 2.032 0.362 22 (40.0) 33 (60.0) 0.378 0.828
Type II 7 (23.3) 23 (76.7) 10 (33.3) 20 (66.7)
Type III 2 (40.0) 3 (60.0) 2 (40.0) 3 (60.0)
No. of PR (%) prior to NCT No. of PR (%) after NCT
- + to about +++ χ2 P value - + to about +++ χ2 P value
Type I 13 (23.6) 42 (76.4) 0.499 0.779 13 (23.6) 42 (76.4) 0.153 0.926
Type II 9 (30.0) 21 (70.0) 8 (26.7) 22 (73.3)
Type III 1 (20.0) 4 (80.0) 1 (20.0) 4 (80.0)
No. of HER2 (%) before NCT No. of HER2 (%) after NCT
– to about + ++ to about ++++ χ2 P value – to about + ++ to about +++ χ2 P value
Type I 32 (58.2) 23 (41.8) 0.743 0.154 39 (70.9) 16 (29.1) 1.142 0.565
Type II 24 (80.0) 6 (20.0) 24 (80.0) 6 (20.0)
Type III 4 (80.0) 1 (20.0) 4 (80.0) 1 (20.0)
aχ2 test. bKruskal-Wallis test.
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the whole breast.
Successive breast subsections were mostly used to
study multifocal primary breast cancer lesions, the scat-
tering mode of breast cancer, Paget’s disease of the
breast and diagnosis of occult breast cancer [16-18]. We
used subserial sectioning of the whole breast to study
the morphology of residual breast cancer and the
changes in the tumor bed. The morphology of residual
tumors after NCT observed by pathological examination
was similar to the shrink patterns examined by im-
aging. Besides the two previously reported types of re-
sidual breast cancer after NCT, for example, solitary,
multifocal and patchlike lesions, a third type of residual
tumor which has one main cancer lesion and one or
two small satellite lesions at least 1.0 cm away from it
was also observed. As the satellite lesions are locatedTable 4 Relationship between types of residual tumors
and the expression changes
Receptor Change Type of residual tumor
Type I Type II Type III P valuea
ER Increase 2 2 0 0.839
No change 41 20 4
Decrease 12 8 1
PR Increase 6 3 0 0.891
No change 36 20 4
Decrease 13 7 1
HER2 Increase 6 2 1 0.545
No change 36 22 4
Decrease 13 6 0
aJonckheere-Terpstra test.away from the main residual tumor, the surgical margin
may appear negative when examined by intraoperative
frozen biopsy, but remaining satellite lesions could
cause local recurrence.
The pattern of residual tumor is thought to relate to
primary tumor size, and multifocal patchlike lesions
more frequently result from larger primary tumors [19].
We have shown that the larger the primary tumors, the
more types II and III residual tumors occurred, which
may be due to vascular distribution and avascular necro-
sis. Age and menstrual status had no bearing on the pat-
tern of residual tumors.
Chagpar et al. suggested that ultrasound and X-ray
examinations cannot identify residual tumors and
chemotherapy-related fibrotic changes, as X-ray under-
estimates the volume of larger tumors and ultrasound
underestimates all breast lumps [20]. We detected nine
cases of calcification with X-ray examination after NCT.
Pathological examination showed that five of the nine
cases of calcification had an intraductal cancer compo-
nent, and four showed small blood vessel changes within
the cancer or necrosis around blood vessels. For type I
residual tumors, there was no difference in tumor size
measured by ultrasound and pathological examination.
However, there was a significant size difference between
measurement by ultrasound and pathological examination
of types II and III residual tumors. Ultrasound may not
have enough sensitivity to penetrate the larger size of types
II and III tumors.
It has been shown that the efficacy of NCT may be
influenced by ER, PR and HER2 status [21-23]. The re-
sponse to chemotherapy was different with regard to the
types of cancer and drugs involved. Patients with triple-
negative breast cancers had better responses to NCT
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possible correlation between ER, PR and HER2 status
with the types of residual tumors after NCT. The levels
of or the change of levels of ER, PR and HER2 were
similar among cancers with different types of residual
tumors after NCT, indicating that the impact of type II
and type III on local recurrence and survival rate was
not related to ER, PR or HER2 status.
Conclusion
Patients with solitary lesions after chemotherapy were
suitable for BCS, whereas the ones with multifocal and
patchlike residual lesions required extra caution. BCS
negative margins of type III residual tumors obtained
from intraoperative frozen biopsies might miss satellite
lesions and lead to local recurrence.
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